X-box Binding Protein 1 is a Potential Immunotherapy Target in Ovarian Cancer
The allure of potentially dramatic and durable responses to immunotherapy has driven the study of several immune checkpoint inhibitor (ICI) agents in ovarian cancer. However, the results of ICI therapy in ovarian cancer have been rather disappointing. It is important to understand the reasons for th...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Genetics |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fgene.2022.818917/full |
| _version_ | 1811313545054257152 |
|---|---|
| author | Yanhui Jiang Lewei Yang Ling Jiang Wenyan Yu Zhongwen Jin Yeqing Qiu Yifeng Liao Jihong Liu Jihong Liu Hongyu Zhang |
| author_facet | Yanhui Jiang Lewei Yang Ling Jiang Wenyan Yu Zhongwen Jin Yeqing Qiu Yifeng Liao Jihong Liu Jihong Liu Hongyu Zhang |
| author_sort | Yanhui Jiang |
| collection | DOAJ |
| description | The allure of potentially dramatic and durable responses to immunotherapy has driven the study of several immune checkpoint inhibitor (ICI) agents in ovarian cancer. However, the results of ICI therapy in ovarian cancer have been rather disappointing. It is important to understand the reasons for the poor efficacy of ICI in ovarian cancer and to look for new targets for immunotherapy. To solve this problem, ovarian cancer–associated datasets were individually collected from The Cancer Genome Atlas (TCGA)、International Cancer Genome Consortium (ICGC)、Genotype-Tissue Expression (GTEx), and comprehensively performed to expression, prognostic, pathological correlation, genomic and immunologic analyses of reported all immune checkpoints by Gene Expression Profiling Interactive Analysis 2 (GEPIA2), Tumor and Immune System Interaction Database (TISIDB), cBio Cancer Genomics Portal (cBioPortal), and Kaplan-Meier Plotter. We concluded that those well-identified immune checkpoints might not be ideal targets for ovarian cancer immunotherapy. Intriguingly, the genomic alteration of X-box binding protein 1 (XBP1), the important mediator of chemotherapy-induced cancer immunogenic cell death, was found to be a potential coregulator of immune checkpoints in ovarian cancer. Importantly, XBP1 was detected to be highly expressed in ovarian cancer compared with normal ovarian tissue, and high XBP1 expression significantly benefits both overall survival (OS) and disease-free survival (DFS) of ovarian cancer patients. More importantly, XBP1 was further observed to be closely related to anti-tumor immunity in ovarian cancer, including multiple T-cell signatures and immunity-killing molecules. In conclusion, upregulating XBP1 rather than targeting immune checkpoints represents a potentially more efficient approach for ovarian cancer therapy. |
| first_indexed | 2024-04-13T10:55:37Z |
| format | Article |
| id | doaj.art-7245164bca094ee0820f3102462ac733 |
| institution | Directory Open Access Journal |
| issn | 1664-8021 |
| language | English |
| last_indexed | 2024-04-13T10:55:37Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Genetics |
| spelling | doaj.art-7245164bca094ee0820f3102462ac7332022-12-22T02:49:32ZengFrontiers Media S.A.Frontiers in Genetics1664-80212022-08-011310.3389/fgene.2022.818917818917X-box Binding Protein 1 is a Potential Immunotherapy Target in Ovarian CancerYanhui Jiang0Lewei Yang1Ling Jiang2Wenyan Yu3Zhongwen Jin4Yeqing Qiu5Yifeng Liao6Jihong Liu7Jihong Liu8Hongyu Zhang9Cancer Center, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, ChinaCancer Center, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, ChinaDepartment of Pathology, Zhuhai Hospital of Integrated Traditional Chinese and Western Medicine, Zhuhai, ChinaCancer Center, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, ChinaCancer Center, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, ChinaCancer Center, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, ChinaCancer Center, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, ChinaDepartment of Gynecology, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, ChinaDepartment of Gynecologic Oncology, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, ChinaCancer Center, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, ChinaThe allure of potentially dramatic and durable responses to immunotherapy has driven the study of several immune checkpoint inhibitor (ICI) agents in ovarian cancer. However, the results of ICI therapy in ovarian cancer have been rather disappointing. It is important to understand the reasons for the poor efficacy of ICI in ovarian cancer and to look for new targets for immunotherapy. To solve this problem, ovarian cancer–associated datasets were individually collected from The Cancer Genome Atlas (TCGA)、International Cancer Genome Consortium (ICGC)、Genotype-Tissue Expression (GTEx), and comprehensively performed to expression, prognostic, pathological correlation, genomic and immunologic analyses of reported all immune checkpoints by Gene Expression Profiling Interactive Analysis 2 (GEPIA2), Tumor and Immune System Interaction Database (TISIDB), cBio Cancer Genomics Portal (cBioPortal), and Kaplan-Meier Plotter. We concluded that those well-identified immune checkpoints might not be ideal targets for ovarian cancer immunotherapy. Intriguingly, the genomic alteration of X-box binding protein 1 (XBP1), the important mediator of chemotherapy-induced cancer immunogenic cell death, was found to be a potential coregulator of immune checkpoints in ovarian cancer. Importantly, XBP1 was detected to be highly expressed in ovarian cancer compared with normal ovarian tissue, and high XBP1 expression significantly benefits both overall survival (OS) and disease-free survival (DFS) of ovarian cancer patients. More importantly, XBP1 was further observed to be closely related to anti-tumor immunity in ovarian cancer, including multiple T-cell signatures and immunity-killing molecules. In conclusion, upregulating XBP1 rather than targeting immune checkpoints represents a potentially more efficient approach for ovarian cancer therapy.https://www.frontiersin.org/articles/10.3389/fgene.2022.818917/fullXBP1immune checkpointimmunogenic cell deathgenomic alterationbioinformatics analysisovarian cancer |
| spellingShingle | Yanhui Jiang Lewei Yang Ling Jiang Wenyan Yu Zhongwen Jin Yeqing Qiu Yifeng Liao Jihong Liu Jihong Liu Hongyu Zhang X-box Binding Protein 1 is a Potential Immunotherapy Target in Ovarian Cancer Frontiers in Genetics XBP1 immune checkpoint immunogenic cell death genomic alteration bioinformatics analysis ovarian cancer |
| title | X-box Binding Protein 1 is a Potential Immunotherapy Target in Ovarian Cancer |
| title_full | X-box Binding Protein 1 is a Potential Immunotherapy Target in Ovarian Cancer |
| title_fullStr | X-box Binding Protein 1 is a Potential Immunotherapy Target in Ovarian Cancer |
| title_full_unstemmed | X-box Binding Protein 1 is a Potential Immunotherapy Target in Ovarian Cancer |
| title_short | X-box Binding Protein 1 is a Potential Immunotherapy Target in Ovarian Cancer |
| title_sort | x box binding protein 1 is a potential immunotherapy target in ovarian cancer |
| topic | XBP1 immune checkpoint immunogenic cell death genomic alteration bioinformatics analysis ovarian cancer |
| url | https://www.frontiersin.org/articles/10.3389/fgene.2022.818917/full |
| work_keys_str_mv | AT yanhuijiang xboxbindingprotein1isapotentialimmunotherapytargetinovariancancer AT leweiyang xboxbindingprotein1isapotentialimmunotherapytargetinovariancancer AT lingjiang xboxbindingprotein1isapotentialimmunotherapytargetinovariancancer AT wenyanyu xboxbindingprotein1isapotentialimmunotherapytargetinovariancancer AT zhongwenjin xboxbindingprotein1isapotentialimmunotherapytargetinovariancancer AT yeqingqiu xboxbindingprotein1isapotentialimmunotherapytargetinovariancancer AT yifengliao xboxbindingprotein1isapotentialimmunotherapytargetinovariancancer AT jihongliu xboxbindingprotein1isapotentialimmunotherapytargetinovariancancer AT jihongliu xboxbindingprotein1isapotentialimmunotherapytargetinovariancancer AT hongyuzhang xboxbindingprotein1isapotentialimmunotherapytargetinovariancancer |